Summit Trail Advisors’s Quest Diagnostics DGX Stock Holding History

Summit Trail Advisors’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.01M	Buy	15,351 +3,714	+32%	+$722K	0.04%	310
2025 Q4	$2.02M	Sell	11,637 -643	-5%	-$117K	0.03%	396
2025 Q3	$2.34M	Buy	12,280 +7,012	+133%	+$1.24M	0.03%	367
2025 Q2	$946K	Buy	5,268 +1,284	+32%	+$223K	0.02%	501
2025 Q1	$674K	Buy	3,984 +2,157	+118%	+$354K	0.02%	209
2024 Q4	$276K	Sell	1,827 -246	-12%	-$38.3K	0.01%	310
2024 Q3	$322K	Sell	2,073 -620	-23%	-$92.6K	0.01%	524
2024 Q2	$369K	Buy	+2,693	New	+$369K	0.01%	436
2018 Q4	–	Sell	-36,360	Closed	-$3.92M	–	149
2018 Q3	$3.92M	Buy	36,360 +35,795	+6,335%	+$3.93M	0.87%	25
2018 Q2	$62K	Sell	565 -23,651	-98%	-$2.46M	0.02%	281
2018 Q1	$1.77M	Buy	24,216 +8,936	+58%	+$915K	0.3%	68
2017 Q4	$1.58M	Buy	+15,280	New	+$1.45M	0.2%	101

Other funds holding DGX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

EIG

EdgePoint Investment Group Toronto, Ontario, Canada $12.5B AUM 31.7% 1-Year Est. Return

Summit Trail Advisors's DGX Position: Q1 2026 in Review

Summit Trail Advisors increased its Quest Diagnostics (DGX) stake by 32% in Q1 2026, buying an estimated $722K and bringing the position to 15,351 shares worth $3.01M. The position accounts for 0.04% of the portfolio, ranked #310.

Summit Trail Advisors first reported a position in DGX in Q4 2017 and has held it in 12 quarters since. The position peaked at $3.92M in Q3 2018. 1,063 funds tracked by Wall St. Rank hold DGX as of Q1 2026.

Summit Trail Advisors held 15,351 shares of Quest Diagnostics worth $3.01M as of Q1 2026.
Summit Trail Advisors bought 3,714 Quest Diagnostics shares in Q1 2026, an estimated $722K.
Quest Diagnostics made up 0.04% of Summit Trail Advisors's portfolio in Q1 2026, its #310 holding.
Summit Trail Advisors first reported a position in Quest Diagnostics in Q4 2017 and has held it in 12 quarters since.
Summit Trail Advisors's Quest Diagnostics position peaked at $3.92M in Q3 2018.
1,063 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2026.

Based on Summit Trail Advisors's 13F filing for Q1 2026, filed 12 May 2026.